Paradoxes and Pitfalls of Interleukin-33 in Atherosclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10123801" target="_blank" >RIV/00179906:_____/12:10123801 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/12:10123801

Výsledek na webu

<a href="http://www.benthamscience.com/open/tocchemj/" target="_blank" >http://www.benthamscience.com/open/tocchemj/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1874241601205010013" target="_blank" >10.2174/1874241601205010013</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Paradoxes and Pitfalls of Interleukin-33 in Atherosclerosis

Popis výsledku v původním jazyce

Atherosclerosis is definitely considered as an inflammatory/immunopathological disease. The long-standing low-grade inflammation is focused on the components of the vessel wall. Initially, this inflammation was assumed to be driven by the pro-inflammatory Th1 cellular and cytokine immune responses. On the basis of accumulating knowledge, however, this view has been specified to include the Th17/Th1 axis which underlies most immunopathological diseases accompanied by sterile inflammation. On the other hand, an anti-inflammatory Th2 cellular and cytokine immune re-sponse attempts to dampen these unfavorable reactions which terminate in full-blown atherosclerosis. Interleukin-33, the novel member of the IL-1 cytokine superfamily, was suggested to take part in the anti-atherogenic response by mediating the Th1-to-Th2 switch of the immune reactions. However, IL-33 is a multifaceted mediator with both pro- and anti-inflammatory activities. IL-33 presents both an extracellular (cytokine-like)

Název v anglickém jazyce

Paradoxes and Pitfalls of Interleukin-33 in Atherosclerosis

Popis výsledku anglicky

Atherosclerosis is definitely considered as an inflammatory/immunopathological disease. The long-standing low-grade inflammation is focused on the components of the vessel wall. Initially, this inflammation was assumed to be driven by the pro-inflammatory Th1 cellular and cytokine immune responses. On the basis of accumulating knowledge, however, this view has been specified to include the Th17/Th1 axis which underlies most immunopathological diseases accompanied by sterile inflammation. On the other hand, an anti-inflammatory Th2 cellular and cytokine immune re-sponse attempts to dampen these unfavorable reactions which terminate in full-blown atherosclerosis. Interleukin-33, the novel member of the IL-1 cytokine superfamily, was suggested to take part in the anti-atherogenic response by mediating the Th1-to-Th2 switch of the immune reactions. However, IL-33 is a multifaceted mediator with both pro- and anti-inflammatory activities. IL-33 presents both an extracellular (cytokine-like)

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Open Clinical Chemistry Journal

ISSN

1874-2416

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

13-20

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—